Copenhagen, Denmark

Helena Mora-Jensen

This inventor holds 1 USPTO granted patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Helena Mora-Jensen. Retrieved from https://idiyas.com/inventor/helena-mora-jensen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Helena Mora-Jensen: Innovator in Imidazolidinone Compounds

Introduction

Helena Mora-Jensen is a notable inventor based in Copenhagen, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly through her innovative work on imidazolidinone compounds. Her research focuses on methods to inhibit deubiquitination, which is crucial for treating various disorders.

Latest Patents

Helena holds 1 patent for her invention titled "Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment." This patent features imidazolidinone compounds and pharmaceutical compositions that are utilized in methods of treating deubiquitination-related disorders in subjects. The compounds also play a role in inhibiting p97-associated deubiquitination.

Career Highlights

Helena works for the United States of America, as represented by the Secretary, Department of Health and Human Services. Her role in this esteemed organization highlights her commitment to advancing healthcare through innovative research and development.

Collaborations

Helena has collaborated with notable colleagues, including William Trenkle and Adrian U Wiestner. These partnerships have further enriched her research and contributed to the success of her inventions.

Conclusion

Helena Mora-Jensen is a pioneering inventor whose work on imidazolidinone compounds has the potential to impact the treatment of deubiquitination-related disorders significantly. Her contributions to the field of pharmaceuticals are commendable and reflect her dedication to innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…